Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Endocrinology
Disease Category: Diabetes Mellitus, Type 1
Trial Information
A study at the onset of Type 1 Diabetes to preserve insulin secretion.
The goal of this study is to find out if two medicines are able
to stop the ongoing destruction of beta cells in your body. The two
medicines are called Mycophenolate mofetil (MMF/CellCept®) and
Daclizumab (DZB/Zenapax®). They work by making your immune system
less active. TrialNet researchers hope that these medicines will
help your beta cells keep the ability to make some insulin and keep
your blood sugar (glucose) levels closer to normal. Even if the
medicines work, you will still need to take insulin shots but your
blood sugar may be easier to control. Better controlled blood sugar
may help reduce long-term complications of diabetes such as
blindness, kidney failure, nerve damage, heart attack and
stroke.
Eligible participants need to be:
- Diagnosed with type 1 diabetes in the last three months
- 12 to 35 years of age
- Willing to comply with intensive diabetes management
Kristen Riley, Recruitment Coordinator
Stanford University School of Medicine
300 Pasteur Drive
Room S-302 Medical Center
Stanford, CA 94305
Phone: 650-725-6577 or 877-232-5182
Fax: 650-725-8375
EMail: kriley@stanford.edu
View Google Map
If you would like to learn more about participating in this study, please send an e-mail message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these
trials.
